Offline dengan aplikasi Player FM !
Next in Pharma: The 2025 Outlook—The Future is Now
Manage episode 472298960 series 3305757
Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights:
- Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction Act
- Examining heightened competition across therapeutic areas and the rapid emergence of rival treatments affecting market economics
- Highlighting the necessity for bold strategic moves and critical capabilities, including AI innovation, portfolio optimization, strategic partnerships, and comprehensive risk management
- Addressing disruptive forces such as geopolitical uncertainty, tariff impacts, and the rise of global innovation influencing pharmaceutical markets
- Emphasizing the urgency for pharma leaders to embrace innovation and transformative strategies to improve healthcare affordability, accessibility, and quality
Speakers:
Greg Rotz, Pharmaceutical & Life Sciences Leader,PwC
Glenn Hunzinger, Health Industries Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC
Linked materials:
Next in pharma 2025: The future is now
Pharmaceutical and life sciences: US Deals 2025 outlook
President Donald J. Trump’s healthcare agenda
For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
59 episode
Manage episode 472298960 series 3305757
Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights:
- Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction Act
- Examining heightened competition across therapeutic areas and the rapid emergence of rival treatments affecting market economics
- Highlighting the necessity for bold strategic moves and critical capabilities, including AI innovation, portfolio optimization, strategic partnerships, and comprehensive risk management
- Addressing disruptive forces such as geopolitical uncertainty, tariff impacts, and the rise of global innovation influencing pharmaceutical markets
- Emphasizing the urgency for pharma leaders to embrace innovation and transformative strategies to improve healthcare affordability, accessibility, and quality
Speakers:
Greg Rotz, Pharmaceutical & Life Sciences Leader,PwC
Glenn Hunzinger, Health Industries Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC
Linked materials:
Next in pharma 2025: The future is now
Pharmaceutical and life sciences: US Deals 2025 outlook
President Donald J. Trump’s healthcare agenda
For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
59 episode
सभी एपिसोड
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.